<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997138</url>
  </required_header>
  <id_info>
    <org_study_id>anakinrapain1</org_study_id>
    <nct_id>NCT01997138</nct_id>
  </id_info>
  <brief_title>Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy</brief_title>
  <official_title>Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy -a Double Blind, Placebo Controlled Study Using Microdialysis Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lovisenberg Diakonale Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project investigates the relation between acute pain and local inflammation. Pain
      reported by the patients for knee arthroscopy are compared with local changes in inflammatory
      mediators by using microdialysis technique. Patients with moderate-to-severe pain are
      included in a randomized placebo-controlled trial of anakinra given intra-articularly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of the recombinant IL-1 receptor antagonist anakinra both on acute pain and post
      operative inflammation will be evaluated. On inclusion, pain intensity will be measured on a
      five-point verbal rating scale (0= no pain, 1=mild pain, 2=moderate pain, 3=severe pain, and
      4=intolerable pain), and on a visual analogue scale (0-100mm). VAS scale will be repeated at
      20, 40, 60, 80, 100, 120, 140, 160, 180 and 200 minutes after inclusion / intervention. The
      patients will also rate pain intensity during a 5 meters walk at 200 minutes (evoked pain).
      The patient will rate pain at rest and evoked pain 24, 48 and 72 h after intervention.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>72h</time_frame>
    <description>Selv reported pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resuce analgesic drug consumption</measure>
    <time_frame>72h</time_frame>
    <description>Need for and consumption of resuce analgesic drug</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>72h</time_frame>
    <description>Selv reported side effect according to CRF</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Knee Injuries</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg in 2 ml saline IA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 2 ml IA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg in 2 ml saline IA</intervention_name>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Otherwise healthy patients (ASA 1 and 2) undergoing knee arthroscopy in general
             anaesthesia.

          2. Being informed about and willing to participate in the study -

        Exclusion Criteria:

          1. Pregnancy or lactation. Fertile women will be asked if they may be pregnant, and
             offered a pregnancy test if there is doubt.

          2. Established osteoarthritis or synovitis

          3. Known intolerance to anakinra

          4. Kidney failure (Creatinine clearance &lt;30ml/min)

          5. History of frequent infectious diseases or immunodeficiency

          6. Heart failure

          7. History of drug -or alcohol abuse

          8. Participation in other synchronous clinical trials

          9. Perioperative steroid treatment, perioperative paracetamol (12 hrs), NSAIDs (24 hrs)
             or COX2-inhibitors (48 hrs).

         10. Use of tourniquet for bloodless field

         11. Strong preoperative pain (VRS â‰¥3)

         12. Intolerable postoperative pain (VRS=4)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lovisenberg Diakonal Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0855</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Leiv Arne Rosseland</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <keyword>pain, inflammation, surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Knee Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

